Tuesday, July 27, 2021

Mad Science, Psychiatric Coercion and the Therapeutic State: An Interview with Dr. David Cohen

76
MIA's Peter Simons interviews David Cohen, PhD, on his path to researching mental health, coercive practices, and discontinuation from psychiatric drugs.

Fighting for the Meaning of Madness: An Interview with Dr. John Read

17
Akansha Vaswani interviews Dr. John Read about the influences on his work and his research on madness, psychosis, and the mental health industry.

Constructing Alternatives to the DSM: An Interview with Dr. Jonathan Raskin

27
Dr. Raskin discusses psychotherapists’ dissatisfaction with current psychiatric diagnostic systems and explores alternatives.

The Effects of Antidepressant Exposure Across Generations: An Interview with Dr. Vance Trudeau

8
Dr. Vance Trudeau discusses his study's finding that antidepressants may have far-reaching, adverse effects that last up to three generations.

Peer-Support Groups Were Right, Guidelines Were Wrong: Dr. Mark Horowitz on Tapering Off Antidepressants

54
In an interview with MIA, Dr. Horowitz discusses his recent article on why tapering off antidepressants can take months or even years.

First-Person Accounts of Madness and Global Mental Health: An Interview with Dr. Gail Hornstein

16
Dr. Gail Hornstein, author of Agnes’s Jacket: A Psychologist’s Search for the Meanings of Madness, discusses the importance of personal narratives and service-user activism in the context of the global mental health movement.

Interview: Researcher Runs Trial on Antidepressant Withdrawal

6
Tony Kendrick, a professor of Primary Care at the University of Southampton, has found through his research and practice that too many people are being prescribed antidepressants long-term without the information and support necessary to get off of them.

Interview: Researchers Deconstruct Ghostwritten Industry Trial for Antidepressant

3
Researchers, Jon Jureidini, Jay Amsterdam and Leemon McHenry, have taken a closer look at the data from a randomized control trial of citalopram (Celexa) that was ghostwritten and then used by the manufacturers to support claims of the drug’s efficacy and safety in the treatment of child and adolescent depression. To get the background on this story, we connected with Dr. Leemon McHenry, an investigator in this study and a lecturer in philosophy at California State University, Northridge.

Follow Us

19,639FansLike
22,949FollowersFollow
0SubscribersSubscribe